Patient Information Leaflet: Everolimus Dr. Reddys 10 mg Tablets EFG
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
1.What is Everolimus Dr. Reddys and what it is used for
2.What you need to know before taking Everolimus Dr. Reddys
3.How to take Everolimus Dr. Reddys
4.Possible side effects
5.Storage of Everolimus Dr. Reddys
6.Contents of the pack and additional information
Everolimus Dr. Reddys is a cancer medication that contains the active ingredient everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.
Everolimus Dr. Reddys is used to treat adult patients with:
Everolimus Dr. Reddys will only be prescribed by a doctor with experience in cancer treatment. Follow the doctor's instructions carefully. They may be different from the general information contained in this leaflet. If you have any doubts about Everolimus Dr. Reddys or the reason why you have been prescribed this medicine, consult your doctor.
Do not take Everolimus Dr. Reddys
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor before starting to take Everolimus Dr. Reddys:
Everolimus Dr. Reddys may also:
Inform your doctorif you experience these symptoms.
During treatment, you will have blood tests performed periodically. These tests will determine the number of cells in your blood (white blood cells, red blood cells, and platelets) to check if Everolimus Dr. Reddys is having an undesirable effect on these cells. You will also have blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are done because these may be affected by treatment with Everolimus Dr. Reddys.
Children and adolescents
Everolimus Dr. Reddys should not be administered to children or adolescents (under 18 years old).
Other medicines and Everolimus Dr. Reddys
Everolimus Dr. Reddys may affect how other medicines work. If you are taking other medicines at the same time as Everolimus Dr. Reddys, your doctor may change the dose of Everolimus Dr. Reddys or of the other medicines.
Inform your doctor or pharmacistif you are using, have used recently, or may need to use any other medicine.
The following may increase the risk of side effects with Everolimus Dr. Reddys:
The following may reduce the effectiveness of Everolimus Dr. Reddys:
You should avoid using these medicines during treatment with Everolimus Dr. Reddys. If you are taking any of them, your doctor may prescribe a different medicine, or may change your dose of Everolimus Dr. Reddys.
Taking Everolimus Dr. Reddys with food and drinks
Avoid grapefruit and grapefruit juice while taking everolimus. It may increase the amount of everolimus in your blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimus Dr. Reddys may cause harm to the fetus and is not recommended for use during pregnancy. Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medicine during pregnancy.
Women who may become pregnant should use a highly effective contraceptive method during treatment and for 8 weeks after stopping treatment. If, despite these measures, you think you may be pregnant, consult your doctorbeforetaking more Everolimus Dr. Reddys.
Breastfeeding
Everolimus Dr. Reddys may harm the breastfeeding baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Inform your doctor if you are breastfeeding.
Female fertility
In some patients treated with Everolimus Dr. Reddys, amenorrhea (absence of menstrual periods) has been observed.
Everolimus Dr. Reddys may affect female fertility. Inform your doctor if you want to have children.
Male fertility
Everolimus Dr. Reddys may affect male fertility. Consult your doctor if you want to be a father.
Driving and operating machines
If you feel abnormally tired (fatigue is a very common side effect), be especially careful when driving or operating machines.
Everolimus Dr. Reddys contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult him before taking this medicine.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg, once a day. Your doctor will inform you how many tablets of Everolimus Dr. Reddys you should take.
If you have liver problems, your doctor may start treatment with a lower dose of Everolimus Dr. Reddys (2.5; 5; or 7.5 mg per day).
If you experience some adverse effects while taking Everolimus Dr. Reddys (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period of time or permanently.
Take Everolimus Dr. Reddys once a day, more or less at the same time, always with food or always without food.
Swallow the tablets whole with a glass of water. The tablets should not be chewed or crushed.
If you take more Everolimus Dr. Reddys than you should
If you forget to take Everolimus Dr. Reddys
If you have forgotten a dose, take the next dose at the time it is due. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Everolimus Dr. Reddys
Do not stop treatment with Everolimus Dr. Reddys unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
STOP treatment with everolimus and seek medical help immediately if you or your child experience any of the following signs of an allergic reaction:
-Intense itching of the skin, with red rash or lumps on the skin
The serious side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
potentially
Rare(may affect up to 1 in 1,000 people)
If you experience any of these side effects, report them to your doctor immediately, as they may be fatal.
Other possible side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
low red blood cell count (anemia)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from available data)
-Reaction at the site of previous radiation therapy, p. skin redness or lung inflammation (the so-called radiation recall syndrome)
-Worsening of side effects from radiation therapy
If these adverse reactions worsen, report them to your doctor and/or pharmacist. Most side effects are mild to moderate and usually disappear if treatment is interrupted for a few days.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
This medication does not require special temperature conditions for storage.
Medicines should not be disposed of through drains or in the trash. Deposit the packaging and themedicines that you no longer need at the SIGREcollection point at the pharmacy. If in doubt, please ask your pharmacist how to dispose of the packaging and the medicines that you no longer need. By doing so, you will help protect the environment.
Composition of Everolimus Dr. Reddys
Appearance of the product and contents of the package
Everolimus Dr. Reddys 10 mg tablets EFG are oval and biconvex tablets of white to off-white color (approximately 16 x 8 mm), engraved with E9VS 10 on one face.
Packaging of 10, 30 or 90 tablets.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible manufacturer
Holder of the Marketing Authorization:
Reddy Pharma Iberia, S.A.
Avda Josep Tarradellas, nº 38
08029 Barcelona
Spain
Telephone: 93 355 49 16
Fax: 93 355 49 61
Responsible manufacturer:
Synthon Hispania S.L.
Castelló 1
Polígono Las Salinas
08830 Sant Boi de Llobregat (Barcelona)
Spain
or
Synthon BV
Microweg 22
6545 CM Nijmegen
Netherlands
or
Betapharm Arzneimittel GmbH
Kobelweg 95
86156, Augsburg
Germany
or
Dr. Reddy's Laboratories (UK) Ltd.
6 Riverview Road, Beverley
HU17 0LD, East Yorkshire
United Kingdom
This medicine is authorized in the Member States of the European Economic Area under the following names:
Member State | Name |
Netherlands | Everolimus Dr. Reddy´s 10 mg, tablets |
Germany | Everolimus beta 10 mg Tablets |
Spain | Everolimus Dr. Reddys 10 mg tablets EFG |
France | Everolimus DR REDDY’S 10 mg, tablet |
Italy | Everolimus Dr. Reddy’s |
United Kingdom | Everolimus Dr. Reddy’s 10 mg Tablets |
Last review date of this leaflet:March 2024
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.